Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications

被引:0
作者
Sudesh Vasdev
Vicki Gill
Pawan Singal
机构
[1] Memorial University of Newfoundland,Discipline of Medicine, Faculty of Medicine, Room H
[2] University of Manitoba,4310, Health Sciences Centre
来源
Cell Biochemistry and Biophysics | 2007年 / 49卷
关键词
Hypertension; Atherosclerosis; Advanced glycation end products; Insulin resistance; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
The vascular diseases, hypertension and atherosclerosis, affect millions of individuals worldwide, and account for a large number of deaths globally. A better understanding of the mechanism of these conditions will lead to more specific and effective therapies. Hypertension and atherosclerosis are both characterized by insulin resistance, and we suggest that this plays a major role in their etiology. The cause of insulin resistance is not known, but may be a result of a combination of genetic and lifestyle factors. In insulin resistance, alterations in glucose and lipid metabolism lead to the production of excess aldehydes including glyoxal and methylglyoxal. These aldehydes react non-enzymatically with free amino and sulfhydryl groups of amino acids of proteins to form stable conjugates called advanced glycation end products (AGEs). AGEs act directly, as well as via receptors to alter the function of many intra- and extracellular proteins including antioxidant and metabolic enzymes, calcium channels, lipoproteins, and transcriptional and structural proteins. This results in endothelial dysfunction, inflammation and oxidative stress. All these changes are characteristic of hypertension and atherosclerosis. Human and animal studies have demonstrated that increased AGEs are also associated with these conditions. A pathological role for AGEs is substantiated by studies showing that therapies that attenuate insulin resistance and/or lower AGEs, are effective in decreasing oxidative stress, lowering blood pressure, and attenuating atherosclerotic vascular changes. These interventions include lipoic acid and other antioxidants, AGE breakers or soluble receptors of AGEs, and aldehyde-binding agents like cysteine. Such therapies may offer alternative specific means to treat hypertension and atherosclerosis. An adjunct therapy may be to implement lifestyle changes such as weight reduction, regular exercise, smoking cessation, and increasing dietary intake of fruits and vegetables that also decrease insulin resistance as well as oxidative stress.
引用
收藏
页码:48 / 63
页数:15
相关论文
共 1023 条
[1]  
Taddei S.(2000)Endothelial dysfunction and hypertension Journal of Nephrology 13 205-210
[2]  
Virdis A.(2004)Oxidative stress in essential hypertension Current Pharmaceutical Design 10 1695-1698
[3]  
Ghiadoni L.(1993)Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of “syndrome X” American Journal of Hypertension 6 123S-134S
[4]  
Salvetti G.(1999)Atherosclerosis – an inflammatory disease The New England Journal of Medicine 340 115-126
[5]  
Salvetti A.(2001)The genesis of atherosclerosis and risk factors: A review Angiology 52 89-98
[6]  
Portaluppi F.(2005)Management of peripheral arterial disease Cardiology in Review 13 61-68
[7]  
Boari B.(2001)The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors Clinical Cardiology 24 V1-V5
[8]  
Manfredini R.(2003)Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease The Journal of Clinical Endocrinology and Metabolism 88 2399-2403
[9]  
Resnick L. M.(1987)Insulin resistance in essential hypertension The New England Journal of Medicine 317 350-357
[10]  
Ross R.(1996)Insulin sensitivity and atherosclerosis Circulaion 93 1809-1817